We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.05B
1-Year Est. Return 125.28%
This Fund
S&P 500
This Quarter Est. Return
-6.12%
1 Year Est. Return
+125.28%
3 Year Est. Return
+334.72%
5 Year Est. Return
+344.07%
10 Year Est. Return
+2,748.76%
AUM
$4.71B
AUM Growth
-$811M
Cap. Flow
-$120M
Cap. Flow %
-2.56%
Top 10 Hldgs %
32.95%
Holding
146
New
21
Increased
16
Reduced
26
Closed
19

Top Buys

Rank Stock Value
1
MRK icon
Merck
MRK
+$114M
2
APLM icon
Apollomics
APLM
+$84.7M
3
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$55.1M
4
ABBV icon
AbbVie
ABBV
+$48.4M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$37.3M

Top Sells

Rank Stock Value
1
BMY icon
Bristol-Myers Squibb
BMY
+$95.2M
2
VECT
VectivBio Holding AG Ordinary Shares
VECT
+$87.7M
3
UNH icon
UnitedHealth
UNH
+$85.6M
4
EW icon
Edwards Lifesciences
EW
+$48.6M
5
BAX icon
Baxter International
BAX
+$48.4M

Sector Composition

Rank Sector Weight
1 Healthcare 96.83%
2 Industrials 1.1%
3 Consumer Staples 0.13%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VRNA
26
DELISTED
Verona Pharma
VRNA
$61.6M 1.31%
3,777,778
– –
RYZB
27
DELISTED
RayzeBio, Inc. Common Stock
RYZB
$58.2M 1.24%
+2,622,909
New +$55.1M
VRTX icon
28
Vertex Pharmaceuticals
VRTX
$125B
$57.5M 1.22%
165,400
– –
SLRN
29
DELISTED
ACELYRIN
SLRN
$54.2M 1.15%
5,326,302
– –
RCM
30
DELISTED
R1 RCM Inc. Common Stock
RCM
$51.9M 1.1%
3,441,000
– –
PCVX icon
31
Vaxcyte
PCVX
$7.76B
$51.3M 1.09%
1,007,148
– –
ABBV icon
32
AbbVie
ABBV
$469B
$49.2M 1.04%
+330,000
New +$48.4M
SIBN icon
33
SI-BONE Inc
SIBN
$801M
$48.7M 1.03%
2,292,531
– –
KROS icon
34
Keros Therapeutics
KROS
$197M
$48.3M 1.03%
1,514,734
– –
APLS
35
DELISTED
Apellis Pharmaceuticals
APLS
$47.9M 1.02%
1,260,500
+350,300
+38% +$15.4M
THRX
36
DELISTED
Theseus Pharmaceuticals, Inc. Common Stock
THRX
$47.6M 1.01%
17,713,600
+479,932
+3% +$1.88M
NBIX icon
37
Neurocrine Biosciences
NBIX
$18.2B
$46.8M 0.99%
415,900
-73,100
-15% -$7.7M
ALPN
38
DELISTED
Alpine Immune Sciences Inc
ALPN
$46.7M 0.99%
4,081,592
– –
CMPX icon
39
Compass Therapeutics
CMPX
$360M
$44.1M 0.94%
22,362,850
– –
NTRA icon
40
Natera
NTRA
$36B
$40.7M 0.87%
920,581
-53,000
-5% -$2.7M
PMVP icon
41
PMV Pharmaceuticals
PMVP
$58.7M
$40.3M 0.86%
6,563,077
– –
RPTX
42
DELISTED
Repare Therapeutics
RPTX
$40.1M 0.85%
3,322,488
– –
SCPH
43
DELISTED
scPharmaceuticals
SCPH
$39.6M 0.84%
5,559,528
– –
NPCE icon
44
Neuropace
NPCE
$494M
$39M 0.83%
4,012,281
– –
TERN
45
DELISTED
Terns Pharmaceuticals
TERN
$38.3M 0.81%
7,619,135
– –
MDGL icon
46
Madrigal Pharmaceuticals
MDGL
$12.5B
$37M 0.79%
253,309
-68,260
-21% -$12.8M
THRD
47
DELISTED
Third Harmonic Bio
THRD
$36.9M 0.78%
5,779,071
– –
UNH icon
48
UnitedHealth
UNH
$387B
$35.3M 0.75%
70,000
-174,000
-71% -$85.6M
SPRY icon
49
ARS Pharmaceuticals
SPRY
$545M
$34.9M 0.74%
9,240,887
+500,000
+6% +$3.28M
AMGN icon
50
Amgen
AMGN
$213B
$34.2M 0.73%
127,300
– –
1
2
3 4 5

Similar funds

HSA
HBK Sorce Advisory Erie, Pennsylvania $5.05B AUM 16.64% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $5.06B AUM 91.14% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.02B AUM 7.87% 1-Year Est. Return
BPWM
Badgley Phelps Wealth Managers Seattle, Washington $5.02B AUM 21.87% 1-Year Est. Return
LFG
Lazard Frères Gestion Paris, France $5.07B AUM 20.66% 1-Year Est. Return
JIM
Jensen Investment Management Lake Oswego, Oregon $5.07B AUM 4.98% 1-Year Est. Return
CTC
Central Trust Company Jefferson City, Missouri $5.08B AUM 25.65% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

OrbiMed's Q3 2023 Portfolio in Review

As of Q3 2023, OrbiMed held 146 positions worth $4.71B, down 15% from $5.52B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

OrbiMed's Q3 2023 filing shows 21 new, 16 increased, 26 reduced and 19 closed positions. Its largest new stake was Merck: 1,055,000 shares worth $109M. The largest sale was Bristol-Myers Squibb, an estimated $95.2M.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, up from 97% a quarter earlier, followed by Industrials and Consumer Staples.

  • OrbiMed's largest Q3 2023 buy was Merck: 1,055,000 shares worth $109M.
  • OrbiMed added most to Apollomics in Q3 2023, an estimated $84.7M increase.
  • OrbiMed's biggest Q3 2023 reduction was UnitedHealth, cutting an estimated $85.6M.
  • OrbiMed fully exited Bristol-Myers Squibb in Q3 2023, selling an estimated $95.2M.
  • OrbiMed's ten largest holdings make up 33% of its $4.71B portfolio in Q3 2023.
  • OrbiMed opened 21 new positions and closed 19 in Q3 2023.
  • OrbiMed's portfolio value fell 15% quarter-over-quarter to $4.71B.

Based on OrbiMed's 13F filing for Q3 2023, filed 14 Nov 2023.